Summary: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.

Top Publications

  1. D Elia E, Fiocca L, Ferrero P, Iacovoni A, Baio P, Medolago G, et al. Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review. J Clin Pharmacol. 2013;53:665-9 pubmed publisher
  2. Tocchetti C, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014;16:358-66 pubmed
    ..Among other hallmarks, oxidative stress is a major contributor to HF pathophysiology. The late INa inhibitor ranolazine has proven effective in treating experimental HF...
  3. Hidalgo Vega A, Ramos Goñi J, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2014;15:917-25 pubmed
    b>Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal ..
  4. van den Berg M, van den Heuvel F, van Tintelen J, Volders P, Van Gelder I. Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. Int J Cardiol. 2014;171:90-2 pubmed publisher
  5. Mittal S. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. J Assoc Physicians India. 2014;62:426-7 pubmed
    ..with QTc prolongation and transient Torsades de pointes following simultaneous use of Ivabradine, Diltiazem and Ranolazine. Effect of Diltiazem on hepatic isoenzyme CYP 3A could be responsible. Such a combination should be avoided.
  6. Fanaroff A, James S, Weisz G, Prather K, Anstrom K, Mark D, et al. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017;69:2304-2313 pubmed publisher
    Chronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control. Ranolazine both treats chronic angina and improves glucose control...
  7. Arnold W, Kline D, Sanderson A, Hawash A, Bartlett A, Novak K, et al. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology. 2017;89:710-713 pubmed publisher
    To determine open-label, pilot study whether ranolazine could improve signs and symptoms of myotonia and muscle stiffness in patients with myotonia congenita (MC). Thirteen participants were assessed at baseline and 2, 4, and 5 weeks...